Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $326.25 Consensus Price Target from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $326.25.

KRYS has been the topic of several research reports. Citigroup upped their price target on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Chardan Capital increased their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. TD Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Guggenheim increased their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, Bank of America raised their target price on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $265.00 on Monday. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $298.30. The firm’s 50-day simple moving average is $269.65 and its 200-day simple moving average is $217.24. The firm has a market cap of $7.75 billion, a PE ratio of 38.69 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The firm had revenue of $107.11 million during the quarter, compared to analyst estimates of $105.30 million. On average, equities analysts predict that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Daniel Janney sold 11,803 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $275.59, for a total transaction of $3,252,788.77. Following the completion of the transaction, the director owned 73,293 shares in the company, valued at approximately $20,198,817.87. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the completion of the sale, the chief accounting officer directly owned 22,366 shares in the company, valued at approximately $5,985,141.60. This trade represents a 3.24% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 104,164 shares of company stock valued at $27,958,328. Insiders own 13.70% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Krystal Biotech by 145.2% during the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after buying an additional 964 shares during the period. AQR Capital Management LLC boosted its position in Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after acquiring an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after purchasing an additional 688 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Krystal Biotech during the first quarter valued at $218,000. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Krystal Biotech by 21.9% during the second quarter. Envestnet Asset Management Inc. now owns 15,116 shares of the company’s stock valued at $2,078,000 after purchasing an additional 2,717 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.